{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:13:31Z","timestamp":1793654011854,"version":"4.5.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11912-022-01289-x","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T06:02:31Z","timestamp":1654236151000},"page":"1425-1432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Surgical Management of Melanoma: Advances and Updates"],"prefix":"10.1007","volume":"24","author":[{"given":"Juan A.","family":"Santamaria-Barria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M. V.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"15","key":"1289_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.19.01464","volume":"38","author":"A Betof Warner","year":"2020","unstructured":"Betof Warner A, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J Clin Oncol. 2020;38(15):1655\u201363.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1289_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"key":"1289_CR3","unstructured":"NCCN clinical practice guidelines in oncology [cited 2021 12\/5\/2021]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf."},{"issue":"11","key":"1289_CR4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377.","journal-title":"Lancet Oncol"},{"key":"1289_CR5","unstructured":"Katz MH. Operative standards for cancer surgery. 2019;2. Wolters Kluwer.\u00a0"},{"key":"1289_CR6","first-page":"CD004835","volume":"4","author":"MJ Sladden","year":"2009","unstructured":"Sladden MJ, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009;4:CD004835.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1289_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/archsurg.1991.01410280036004","volume":"126","author":"U Veronesi","year":"1991","unstructured":"Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126(4):438\u201341.","journal-title":"Arch Surg"},{"issue":"3","key":"1289_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00000658-199309000-00005","volume":"218","author":"CM Balch","year":"1993","unstructured":"Balch CM, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218(3):262\u20137 (discussion 267-9).","journal-title":"Ann Surg"},{"issue":"9","key":"1289_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1809::AID-CNCR8>3.0.CO;2-6","volume":"77","author":"U Ringborg","year":"1996","unstructured":"Ringborg U, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer. 1996;77(9):1809\u201314.","journal-title":"Cancer"},{"issue":"8","key":"1289_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/cncr.11272","volume":"97","author":"D Khayat","year":"2003","unstructured":"Khayat D, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97(8):1941\u20136.","journal-title":"Cancer"},{"issue":"8","key":"1289_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMoa030681","volume":"350","author":"JM Thomas","year":"2004","unstructured":"Thomas JM, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350(8):757\u201366.","journal-title":"N Engl J Med"},{"issue":"9803","key":"1289_CR12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","volume":"378","author":"P Gillgren","year":"2011","unstructured":"Gillgren P, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378(9803):1635\u201342.","journal-title":"Lancet"},{"issue":"6","key":"1289_CR13","first-page":"419","volume":"46","author":"PI Haigh","year":"2003","unstructured":"Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg. 2003;46(6):419\u201326.","journal-title":"Can J Surg"},{"issue":"10","key":"1289_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/archsurg.137.10.1101","volume":"137","author":"MB Lens","year":"2002","unstructured":"Lens MB, et al. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg. 2002;137(10):1101\u20135.","journal-title":"Arch Surg"},{"key":"1289_CR15","doi-asserted-by":"publisher","first-page":"h3708","DOI":"10.1136\/bmj.h3708","volume":"351","author":"F Macbeth","year":"2015","unstructured":"Macbeth F, et al. Melanoma: summary of NICE guidance. BMJ. 2015;351:h3708.","journal-title":"BMJ"},{"issue":"12","key":"1289_CR16","first-page":"A6136","volume":"157","author":"L Veerbeek","year":"2013","unstructured":"Veerbeek L, et al. Revision of the national guideline \u2018Melanoma.\u2019 Ned Tijdschr Geneeskd. 2013;157(12):A6136.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1289_CR17","unstructured":"Clinical practice guidelines for the diagnosis and management of melanoma [cited 2021 12\/5\/2021]; Available from: https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma#_ga=2.8765621.1604953279.1638706803-1317310954.1638706803."},{"key":"1289_CR18","unstructured":"F. Wright, L.H.S., S. Kellett, A. Easson, C. Murray, J. Toye, D. McCready, C. Nessim, D., N.L.H. Ghazarian, S. Johnson, D. Goldstein, T. Petrella, and the Melanoma Disease, and S. Group. Primary excision margins and sentinel lymph node biopsy in cutaneous melanoma. 2017; Available from: https:\/\/www.cancercareontario.ca\/sites\/ccocancercare\/files\/guidelines\/full\/pebc8-2v2f.pdf."},{"issue":"4","key":"1289_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1245\/s10434-015-4575-3","volume":"23","author":"LE Haydu","year":"2016","unstructured":"Haydu LE, et al. Minimum safe pathologic excision margins for primary cutaneous melanomas (1\u20132 mm in thickness): analysis of 2131 patients treated at a single center. Ann Surg Oncol. 2016;23(4):1071\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1289_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1046\/j.1087-0024.2003.09118.x","volume":"9","author":"JA Newton-Bishop","year":"2004","unstructured":"Newton-Bishop JA, et al. A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc. 2004;9(2):152\u20139.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"9","key":"1289_CR21","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","volume":"25","author":"MD Moncrieff","year":"2018","unstructured":"Moncrieff MD, et al. 1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study. Ann Surg Oncol. 2018;25(9):2541\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1289_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/DSS.0000000000002668","volume":"47","author":"JS Barklund","year":"2021","unstructured":"Barklund JS, et al. Utilization patterns of fellowship-trained mohs surgeons in the treatment of melanoma in situ and melanoma. Dermatol Surg. 2021;47(6):814\u20135.","journal-title":"Dermatol Surg"},{"issue":"12","key":"1289_CR23","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/DSS.0000000000003268","volume":"47","author":"AE Krausz","year":"2021","unstructured":"Krausz AE, et al. Systematic review of technical variations for Mohs micrographic surgery for melanoma. Dermatol Surg. 2021;47(12):1539\u201344.","journal-title":"Dermatol Surg"},{"issue":"4","key":"1289_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","volume":"19","author":"SM Swetter","year":"2021","unstructured":"Swetter SM, et al. NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021. J Natl Compr Canc Netw. 2021;19(4):364\u201376.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"1289_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1309\/AJCPWSDDHLLW40WI","volume":"140","author":"BJ Hall","year":"2013","unstructured":"Hall BJ, et al. Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. Am J Clin Pathol. 2013;140(5):635\u201342.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"1289_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609.","journal-title":"N Engl J Med"},{"issue":"4","key":"1289_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/SLA.0000000000003405","volume":"273","author":"JF Thompson","year":"2021","unstructured":"Thompson JF, et al. Preoperative ultrasound assessment of regional lymph nodes in melanoma patients does not provide reliable nodal staging: results from a large multicenter trial. Ann Surg. 2021;273(4):814\u201320.","journal-title":"Ann Surg"},{"issue":"4","key":"1289_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jamcollsurg.2020.11.014","volume":"232","author":"KK Broman","year":"2021","unstructured":"Broman KK, et al. Surveillance of sentinel node-positive melanoma patients with reasons for exclusion from MSLT-II: multi-institutional propensity score matched analysis. J Am Coll Surg. 2021;232(4):424\u201331.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"1289_CR29","doi-asserted-by":"publisher","first-page":"308","DOI":"10.6004\/jnccn.2009.0023","volume":"7","author":"RH Andtbacka","year":"2009","unstructured":"Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7(3):308\u201317.","journal-title":"J Natl Compr Canc Netw"},{"issue":"35","key":"1289_CR30","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","volume":"31","author":"D Han","year":"2013","unstructured":"Han D, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31(35):4387\u201393.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1289_CR31","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1245\/s10434-014-3641-6","volume":"21","author":"C Mitteldorf","year":"2014","unstructured":"Mitteldorf C, et al. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. Ann Surg Oncol. 2014;21(7):2252\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1289_CR32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ejso.2013.02.025","volume":"39","author":"PN Broer","year":"2013","unstructured":"Broer PN, et al. Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy. Eur J Surg Oncol. 2013;39(7):681\u20135.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"1289_CR33","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1245\/s10434-013-2883-z","volume":"20","author":"D Han","year":"2013","unstructured":"Han D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol. 2013;20(7):2345\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"1289_CR34","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1245\/s10434-012-2468-2","volume":"19","author":"A Mohebati","year":"2012","unstructured":"Mohebati A, et al. The role of sentinel lymph node biopsy in the management of head and neck desmoplastic melanoma. Ann Surg Oncol. 2012;19(13):4307\u201313.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1289_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1245\/s10434-019-07699-9","volume":"27","author":"AAG Nijhuis","year":"2020","unstructured":"Nijhuis AAG, et al. Sentinel node biopsy for melanoma patients with a local recurrence or in-transit metastasis. Ann Surg Oncol. 2020;27(2):561\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1289_CR36","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.2967\/jnumed.114.153643","volume":"56","author":"A Jimenez-Heffernan","year":"2015","unstructured":"Jimenez-Heffernan A, et al. Results of a prospective multicenter international atomic energy agency sentinel node trial on the value of SPECT\/CT over planar imaging in various malignancies. J Nucl Med. 2015;56(9):1338\u201344.","journal-title":"J Nucl Med"},{"issue":"4","key":"1289_CR37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/lary.25024","volume":"125","author":"AK Remenschneider","year":"2015","unstructured":"Remenschneider AK, et al. The predictive value of single-photon emission computed tomography\/computed tomography for sentinel lymph node localization in head and neck cutaneous malignancy. Laryngoscope. 2015;125(4):877\u201382.","journal-title":"Laryngoscope"},{"issue":"11","key":"1289_CR38","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/cncr.22320","volume":"107","author":"CJ Gannon","year":"2006","unstructured":"Gannon CJ, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107(11):2647\u201352.","journal-title":"Cancer"},{"issue":"6","key":"1289_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1245\/ASO.2003.10.001","volume":"10","author":"WR Wrightson","year":"2003","unstructured":"Wrightson WR, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10(6):676\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"1289_CR40","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med"},{"issue":"32","key":"1289_CR41","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, et al. Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1289_CR42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/JCO.2013.50.7681","volume":"32","author":"S Pasquali","year":"2014","unstructured":"Pasquali S, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32(9):935\u201341.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1289_CR43","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1245\/s10434-010-1208-8","volume":"17","author":"RE Brown","year":"2010","unstructured":"Brown RE, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2010;17(12):3330\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"1289_CR44","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cncr.33483","volume":"127","author":"KK Broman","year":"2021","unstructured":"Broman KK, et al. Active surveillance of patients who have sentinel node positive melanoma: an international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021;127(13):2251\u201361.","journal-title":"Cancer"},{"issue":"6","key":"1289_CR45","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1245\/s10434-013-2880-2","volume":"20","author":"C Nessim","year":"2013","unstructured":"Nessim C, et al. How often do level III nodes bear melanoma metastases and does it affect patient outcomes? Ann Surg Oncol. 2013;20(6):2056\u201364.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1289_CR46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s10147-015-0944-y","volume":"21","author":"A Tsutsumida","year":"2016","unstructured":"Tsutsumida A, et al. Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan. Int J Clin Oncol. 2016;21(4):796\u2013800.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"1289_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/CMR.0000000000000041","volume":"24","author":"C Slagelse","year":"2014","unstructured":"Slagelse C, et al. Persistent postoperative pain and sensory changes following lymph node excision in melanoma patients: a topical review. Melanoma Res. 2014;24(2):93\u20138.","journal-title":"Melanoma Res"},{"issue":"1\u20132","key":"1289_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/ans.13526","volume":"87","author":"JE Theodore","year":"2017","unstructured":"Theodore JE, et al. Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ J Surg. 2017;87(1\u20132):44\u20138.","journal-title":"ANZ J Surg"},{"issue":"3","key":"1289_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jamcollsurg.2015.11.010","volume":"222","author":"JW Jakub","year":"2016","unstructured":"Jakub JW, et al. Training high-volume melanoma surgeons to perform a novel minimally invasive inguinal lymphadenectomy: report of a prospective multi-institutional trial. J Am Coll Surg. 2016;222(3):253\u201360.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"1289_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256\u201363.","journal-title":"Nat Med"},{"issue":"2","key":"1289_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301\u20139.","journal-title":"Nat Med"},{"key":"1289_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2021.02.012","volume":"148","author":"JM Versluis","year":"2021","unstructured":"Versluis JM, et al. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer. 2021;148:51\u20137.","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"1289_CR53","doi-asserted-by":"publisher","first-page":"10002","DOI":"10.1200\/JCO.2020.38.15_suppl.10002","volume":"38","author":"CU Blank","year":"2020","unstructured":"Blank CU, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38(15_suppl):10002.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1289_CR54","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.3747\/co.27.6523","volume":"27","author":"FC Wright","year":"2020","unstructured":"Wright FC, et al. Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline. Curr Oncol. 2020;27(3):e318\u201325.","journal-title":"Curr Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01289-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01289-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01289-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T02:39:00Z","timestamp":1667097540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01289-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01289-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"4 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}